The PPARγ agonist rosiglitazone is antifibrotic for scleroderma lung fibroblasts: Mechanisms of action and differential racial effects

Pulmonary Medicine

Volumn , Issue , 2012, Pages

  Bogatkevich, Galina S ^a   Highland, Kristin B ^a   Akter, Tanjina ^a   Silver, Richard M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ANTIFIBROTIC AGENT; BETA ACTIN; COLLAGEN TYPE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERSTITIAL COLLAGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; SCATTER FACTOR RECEPTOR;

ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; LUNG FIBROBLAST; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACE DIFFERENCE; SCLERODERMA;

EID: 84863964211     PISSN: 20901836     EISSN: 20901844     Source Type: Journal    
DOI: 10.1155/2012/545172     Document Type: Article

References (34)

1. Consoli A., Devangelio E., Thiazolidinediones and inflammation Lupus 2005 14 9 794 797 (Pubitemid 41413314)
2. Becker J., Delayre-Orthez C., Frossard N., Pons F., Regulation of inflammation by PPARγs: a future approach to treat lung inflammatory diseases? Fundamental and Clinical Pharmacology 2006 20 5 429 447 (Pubitemid 44393958)
3. Patel H. J., Belvisi M. G., Bishop-Bailey D., Yacoub M. H., Mitchell J. A., Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy Journal of Immunology 2003 170 5 2663 2669 (Pubitemid 36245659)
4. Bonfield T. L., Farver C. F., Barna B. P., Malur A., Abraham S., Raychaudhuri B., Kavuru M. S., Thomassen M. J., Peroxisome proliferator- activated receptor- is deficient in alveolar macrophages from patients with alveolar proteinosis American Journal of Respiratory Cell and Molecular Biology 2003 29 6 677 682 (Pubitemid 38045936)
5. Wang A. C. C., Dai X., Luu B., Conrad D. J., Peroxisome proliferator-activated receptor- regulates airway epithelial cell activation American Journal of Respiratory Cell and Molecular Biology 2001 24 6 688 693 (Pubitemid 32550590)
6. Shi-Wen X., Eastwood M., Stratton R. J., Denton C. P., Leask A., Abraham D. J., Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts Rheumatology 2010 49 2 259 263
7. Wei J., Ghosh A. K., Sargent J. L., Komura K., Wu M., Huang Q. Q., Jain M., Whitfield M. L., Feghali-Bostwick C., Varga J., PPARγ downregulation by TGF in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis PLoS One 2010 5 11
8. Culver D. A., Barna B. P., Raychaudhuri B., Bonfield T. L., Abraham S., Malur A., Farver C. F., Kavuru M. S., Thomassen M. J., Peroxisome proliferator-activated receptor activity is deficient in alveolar macrophages in pulmonary sarcoidosis American Journal of Respiratory Cell and Molecular Biology 2004 30 1 1 5 (Pubitemid 38085252)
9. Ghosh A. K., Bhattacharyya S., Lakos G., Chen S. J., Mori Y., Varga J., Disruption of transforming growth factor signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor Arthritis Rheumatism 2004 50 4 1305 1318 (Pubitemid 38480842)
10. Kapoor M., McCann M., Liu S., Huh K., Denton C. P., Abraham D. J., Leask A., Loss of peroxisome proliferator-activated receptor in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis Arthritis Rheumatism 2009 60 9 2822 2829
11. Wu M., Melichian D. S., Chang E., Warner-Blankenship M., Ghosh A. K., Varga J., Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor- The American Journal of Pathology 2009 174 2 519 533
12. Burgess H. A., Daugherty L. E., Thatcher T. H., Lakatos H. F., Ray D. M., Redonnet M., Phipps R. P., Sime P. J., PPARγ agonists inhibit TGF- induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis The American Journal of Physiology 2005 288 6 L1146 L1153
13. Bartram U., Speer C. P., The role of transforming growth factor in lung development and disease Chest 2004 125 2 754 765 (Pubitemid 38223659)
14. Silver R. M., Miller K. S., Kinsella M. B., Smith E. A., Schabel S. I., Evaluation and management of scleroderma lung disease using bronchoalveolar lavage The American Journal of Medicine 1990 88 5 470 476 (Pubitemid 20168722)
15. Ludwicka A., Trojanowska M., Smith E. A., Baumann M., Strange C., Korn J. H., Smith T., LeRoy E. C., Silver R. M., Growth and characterization of fibroblasts obtained from bronchoalveolar lavage of patients with scleroderma Journal of Rheumatology 1992 19 11 1716 1723
16. Bogatkevich G. S., Ludwicka-Bradley A., Highland K. B., Hant F., Nietert P. J., Singleton C. B., Feghali-Bostwick C. A., Silver R. M., Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: possible role in systemic sclerosis Arthritis Rheumatism 2007 56 7 2432 2442 (Pubitemid 47173591)
17. Bogatkevich G. S., Gustilo E., Oates J. C., Feghali-Bostwick C., Harley R. A., Silver R. M., Ludwicka-Bradley A., Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts The American Journal of Physiology 2005 288 1 L190 L201
18. Bogatkevich G. S., Ludwicka-Bradley A., Highland K. B., Hant F., Nietert P. J., Singleton C. B., Silver R. M., Down-regulation of collagen and connective tissue growth factor expression with hepatocyte growth factor in lung fibroblasts from white scleroderma patients via two signaling pathways Arthritis Rheumatism 2007 56 10 3468 3477 (Pubitemid 47585443)
19. Bogatkevich G. S., Ludwicka-Bradley A., Singleton C. B., Bethard J. R., Silver R. M., Proteomic analysis of CTGF-activated lung fibroblasts: identification of IQGAP1 as a key player in lung fibroblast migration The American Journal of Physiology 2008 295 4 L603 L611
20. Zhang J., Fang N. Y., Gao P. J., Wu L. Y., Han W. Q., Guo S. J., Shen W. L., Zhu D. L., Peroxisome proliferator-activated receptor- agonists attenuate angiotensin II-induced collagen type I expression in adventitial fibroblasts Clinical and Experimental Pharmacology and Physiology 2008 35 1 72 77 (Pubitemid 350197686)
21. Li Y., Wen X., Spataro B. C., Hu K., Dai C., Liu Y., Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor- agonists Journal of the American Society of Nephrology 2006 17 1 54 65
22. Highland K. B., Silver R. M., Clinical aspects of lung involvement: lessons from idiopathic pulmonary fibrosis and the scleroderma lung study Current Rheumatology Reports 2005 7 2 135 141
23. Ostojic P., Cerinic M. M., Silver R., Highland K., Damjanov N., Interstitial lung disease in systemic sclerosis Lung 2007 185 4 211 220 (Pubitemid 47101358)
24. Nietert P. J., Mitchell H. C., Bolster M. B., Shaftman S. R., Tilley B. C., Silver R. M., Racial variation in clinical and immunological manifestations of systemic sclerosis Journal of Rheumatology 2006 33 2 263 268 (Pubitemid 43209301)
25. Steen V. D., Autoantibodies in systemic sclerosis Seminars in Arthritis and Rheumatism 2005 35 1 35 42 (Pubitemid 41111469)
26. Greidinger E. L., Flaherty K. T., White B., Rosen A., Wigley F. M., Wise R. A., African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease Chest 1998 114 3 801 807 (Pubitemid 28433744)
27. McNearney T. A., Reveille J. D., Fischbach M., Friedman A. W., Lisse J. R., Goel N., Tan F. K., Zhou X., Ahn C., Feghali-Bostwick C. A., Fritzler M., Arnett F. C., Mayes M. D., Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors Arthritis Rheumatism 2007 57 2 318 326 (Pubitemid 47164096)
28. Lakatos H. F., Thatcher T. H., Kottmann R. M., Garcia T. M., Phipps R. P., Sime P. J., The role of PPARγs in lung fibrosis PPARγ Research 2007
29. Milam J. E., Keshamouni V. G., Phan S. H., Hu B., Gangireddy S. R., Hogaboam C. M., Standiford T. J., Thannickal V. J., Reddy R. C., PPARγ- agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis The American Journal of Physiology 2008 294 5 L891 L901
30. Genovese T., Cuzzocrea S., Di Paola R., Mazzon E., Mastruzzo C., Catalano P., Sortino M., Crimi N., Caputi A. P., Thiemermann C., Vancheri C., Effect of rosiglitazone and 15-deoxy-12,14-prostaglandin J2 on bleomycin-induced lung injury European Respiratory Journal 2005 25 2 225 234 (Pubitemid 40246521)
31. Zhao C., Chen W., Yang L., Chen L., Stimpson S. A., Diehl A. M., PPARγ agonists prevent TGF 1/Smad3-signaling in human hepatic stellate cells Biochemical and Biophysical Research Communications 2006 350 2 385 391 (Pubitemid 44498647)
32. Masamune A., Satoh K., Sakai Y., Yoshida M., Satoh A., Shimosegawa T., Ligands of peroxisome proliferator-activated receptor- induce apoptosis in AR42J cells Pancreas 2002 24 2 130 138 (Pubitemid 34171288)
33. Teresi R. E., Shaiu C. W., Chen C. S., Chatterjee V. K., Waite K. A., Eng C., Increased PTEN expression due to transcriptional activation of PPARγ by Lovastatin and Rosiglitazone International Journal of Cancer 2006 118 10 2390 2398
34. Hoshino K., Satoh T., Kawaguchi Y., Kuwana M., Association of hepatocyte growth factor promoter polymorphism with severity of interstitial lung disease in Japanese patients with systemic sclerosis Arthritis Rheumatism 2011 63 8 2465 2472